MANI, INC. (7730) Stock Price

Mani is a company primarily engaged in the manufacturing and sales of surgical instruments and dental materials for medical use. The company's main products include surgical items such as skin suture devices and ophthalmic knives, sutures with surgical needles and Ailes eyed needles (the needle material used in sutures), dental root canal treatment equipment, rotary cutting instruments, and dental restorative materials.

The company's primary customers are distributors and suture manufacturers, with hospitals and dental clinics supplied mainly through distribution networks. Mani secures stable revenue through continuous sales of consumables such as sterilized sutures with needles and dental consumables, while adding value through sales of surgical equipment and specialized devices. Additionally, the company operates production and sales bases overseas, making sales in international markets an important revenue source.

The business is divided into three main segments: surgical-related, Ailes needle-related, and dental-related. In the surgical segment, Mani manufactures and sells skin suture devices, trocars, and deep suture devices. In the Ailes needle segment, it produces sutures with needles and needle materials. In the dental segment, it manufactures and sells reamers, files, nickel-titanium files, various burs, and restorative materials.

Based on its Medium-Term Management Plan 2029, the company aims to transform into a stable, highly profitable business and achieve sustainable growth. Specifically, it targets increasing net sales from 30 billion yen in fiscal 2025 to 45 billion yen by 2029, and raising operating profit from 8.2 billion yen to 14.5 billion yen (approximately 32% margin). The company plans to improve operating cash flow by 1.5 times from current levels, has secured a 20 billion yen M&A investment budget to strengthen growth investments, and targets a DOE (dividend and return on equity indicator) of 8% as a guideline for shareholder returns.

The company has identified three priority investment areas: surgical products (particularly ophthalmic knives), needle-related products, and dental products. In the ophthalmic field, it aims to increase global market share for knives from 30% to 50% and expand its product lineup for glaucoma and vitreous surgery. In the needle business, it will maintain and strengthen its position as the world's second-largest independent manufacturer while investing in high-value-added products such as micro needles and robotic surgery instruments to differentiate itself. In dentistry, the company will expand its endodontic treatment product portfolio and improve profitability of restorative materials, aiming to move away from price competition through superior product quality and clinical value.

The company positions international expansion as a key growth driver, focusing on sales growth in North America, Europe, and Asia. It will expand locally-rooted sales operations through a global five-hub structure centered on regional headquarters, leveraging strategic alliances and M&A to capture new business opportunities. Specific initiatives include strengthening sales partnerships with U.S.-based MST, co-creation with pharmaceutical companies, maintaining competitiveness through China's government procurement (GPO) compliance and cost reduction, and shifting investment focus from production equipment to growth areas.

The company places technological innovation at the core of its management foundation and is advancing efforts to accelerate development speed through R&D process reform. It will accelerate development of micro products and high-precision components through open collaborative development, next-generation processing technologies, and application of micro-processing techniques to drive product differentiation. Additionally, the company is advancing cost reduction through business digitalization and supply chain reform, while simultaneously strengthening sustainability initiatives including talent development, diversity promotion, and environmental impact reduction.